10-Q · May 14, 2026
Valion Bio, Inc. reported disappointing Q1 2026 financial results with total revenue of $0, unchanged from the previous year, while posting an EPS of -$2.23, a modest improvement from -$2.52 a year ago. Operating…
Earnings analysis · 10-Q
VBIO earnings analysis
Filed August 14, 2026 · Our reading of the company's report
The latest report
The supplied 10-Q excerpt does not include income statement, balance sheet, cash flow, or segment data, so current-period revenue, margins, EPS, liquidity, and free cash flow cannot be assessed. Management reported…
Read full summary
The supplied 10-Q excerpt does not include income statement, balance sheet, cash flow, or segment data, so current-period revenue, margins, EPS, liquidity, and free cash flow cannot be assessed. Management reported effective disclosure controls but also disclosed a material weakness in internal control over financial reporting as of December 31, 2025. The principal updated risks are the proposed 1-for-5 to 1-for-50 reverse split, potential failure to maintain Nasdaq's $1.00 minimum bid requirement, and possible remediation costs.
What stood out
-
Disclosure Controls Deemed Effective
Management concluded that disclosure controls and procedures were effective as of the end of the period covered by the Quarterly Report.
-
Control Remediation Underway
The company is evaluating accounting and finance personnel resources and continuing to enhance processes and procedures to remediate the material weakness identified as of December 31, 2025.
-
No New Unregistered Sales or Repurchases
The filing reports no unregistered securities sales during the quarter ended June 30, 2026, beyond those previously disclosed in a Form 8-K, and no equity repurchases during the 3 months ended June 30, 2026.
What to watch
-
Reverse Split Could Reduce Value and Liquidity
Stockholders were asked to authorize a reverse stock split between 1-for-5 and 1-for-50. The filing warns that the reduced share count could adversely affect liquidity and that the stock price could decline after implementation.
-
Nasdaq Minimum Bid Compliance Risk
The company plans the reverse stock split to help satisfy Nasdaq's minimum bid price requirement of $1.00, but states there is no assurance the post-split price will remain compliant or that continued Nasdaq Capital Market listing will be maintained.
-
Material Weakness and Remediation Costs
Management identified a material weakness in internal control over financial reporting as of December 31, 2025, caused by the small size of the accounting and financial reporting team. Remediation may require retaining a third party and could result in material future costs.
Management's outlook
No quantitative revenue or EPS outlook was provided in the supplied 10-Q. The filing states that the reverse split may be implemented within 12 months after stockholder approval, but provides no operating guidance.
Earlier filings 1
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.